SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is trending due to heightened community speculation surrounding a potential supply shock, upcoming exchange burns, and ongoing legal developments. Investors are actively discussing the possibility of a major recovery, with many sharing long-term price predictions and strategies for navigating market volatility.

LUNA is the native token of the Terra blockchain, a decentralized platform designed to host applications and provide financial tools. Following a transition from Terra Classic, the new Terra chain was established through a community-led governance proposal to focus on a decentralized economy without a stablecoin. As the foundational asset of the protocol, LUNA functions as the engine for the network where value moves as users pay gas fees to interact with decentralized applications. Its primary value proposition lies in its ability to scale rewards for stakers as developer activity and transaction volumes grow within the ecosystem.  The network maintains security through a Proof of Stake system using the Tendermint consensus mechanism, where 130 independent validators compare transactions to ensure the integrity of the blockchain. Users who do not want to run their own node can delegate their tokens to these validators to help record and verify data. To ensure accountability, the protocol employs slashing, a penalty that removes a small portion of staked tokens if a validator misbehaves or goes offline.  Originally created by Terraform Labs, the project has evolved into a community-governed model where independent developer groups and users maintain the protocol. Terraform Labs currently manages a claims portal for users impacted by previous network events as part of ongoing legal and bankruptcy proceedings. The token serves multiple roles, including paying for gas fees to interact with dApps , providing voting power for governance proposals , and earning rewards through a fixed 7% annual inflation rate.

Terra 2.0

Terra 2.0 (LUNA) is currently sparking intense debate within the crypto community, driven by ongoing legal developments surrounding the founder and speculation regarding the project's long-term viability. Investors remain polarized, with some closely monitoring potential governance and ecosystem upgrades while others express skepticism, often drawing comparisons to past market volatility and drawing parallels to Terra Classic (LUNC).

TerraClassicUSD (USTC) was originally launched as an algorithmic stablecoin within the Terra ecosystem, designed to maintain a peg to the US dollar through an automated market-Module mechanism with LUNA (now LUNC). However, following the collapse of the Terra ecosystem in May 2022, the core stabilizing mechanism was disabled, and USTC lost its peg to the US dollar.  Since then, USTC has been a freely traded digital asset, with its price determined purely by market supply and demand. It no longer functions as a stablecoin, nor does it have an active peg-maintenance mechanism.  USTC remains an integral part of the Terra Classic ecosystem, where it continues to be used for various purposes, including DeFi applications , gas fees and trading. Unlike traditional fiat-backed assets, USTC’s value fluctuates based on market conditions and community participation.

TerraClassicUSD

TerraClassicUSD is gaining momentum as investors react to ongoing ecosystem governance proposals, active token burn initiatives, and optimistic speculation regarding a potential repeg. The community is closely monitoring legal developments and potential regulatory shifts, with many traders focused on volume-driven price movements and increased staking activity within the broader Terra Luna ecosystem.

ProShares Trust - ProShares Ultra 7-10 Year Treasury 2x Shares

ProShares Ultra 7-10 Year Treasury

ProShares Ultra 7-10 Year Treasury (UST) is seeing active discussion as investors weigh its role in macro hedging against broader bond market volatility and central bank policy uncertainty. Community sentiment remains split, with traders monitoring how shifting interest rates and evolving fiscal conditions impact the ETF's performance relative to other safe-haven assets.

$ORDI : first token deployed on Bitcoin Ordinals, with a 21 million supply. $DOGI : first token deployed on Dogecoin Ordinals, with a 21 million supply. The First DRC-20 token in the history

dogi

The DRC-20 token DOGI is gaining significant traction as community members emphasize the growth of the Doginals ecosystem and upcoming platform developments. Investors are actively discussing the token's relationship to the Dogecoin network and its potential as a memecoin play alongside established BRC-20 standards.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing increased community chatter as traders weigh the upcoming Goliath mainnet launch against persistent skepticism regarding its long-term utility and past price volatility. While some participants are aggressively accumulating in anticipation of institutional adoption, others remain vocal about the project's lack of confirmed commercial partnerships and recurring patterns of speculative price swings.

Constellation Energy Corp. engages in the generation, supply, and marketing of clean electricity, and renewable energy products and solutions. The firm also offers wholesale energy, retail products and services. It operates under the following geographical segments: Mid-Atlantic, Midwest, New York, Electric Reliability Council of Texas (ERCOT), and Other Power Regions Segment. The company was founded in 1960 and is headquartered in Baltimore, MD.

Constellation Energy Corporation

Constellation Energy Corp

Constellation Energy is trending as investors weigh potential federal regulatory shifts impacting power pricing alongside its critical role in meeting massive electricity demand from AI data centers. Community discussions remain focused on its position as a primary beneficiary of nuclear-powered grid infrastructure, despite recent market volatility and debates over the valuation impact of proposed grid auction changes.

Hubbell, Inc. engages in the designing, manufacturing, and sale of electrical and electronic products for non-residential and residential construction, industrial, and utility applications. It operates through the Electrical Solutions and Utility Solutions segments. The Electrical Solutions segment manufactures and sells wiring and electrical, lighting fixtures, and controls for indoor and outdoor applications as well as specialty lighting and communications products. The Utility Solutions segment is involved in the design, manufacture, and sale of electrical distribution, transmission, substation, and telecommunications products. The company was founded by Harvey Hubbell II in 1888 and is headquartered in Shelton, CT.

Hubbell Inc.

Hubbell is trending as a critical pick-and-shovel play for the AI power trade, with investors highlighting its role in the data center infrastructure buildout and essential grid modernization efforts. The community is focused on the stock's strong order backlogs and consistent growth, positioning it as a structural beneficiary of the ongoing transition to AI-driven electrical demand.

Chip

CHIP is seeing intense debate as investors weigh strong AI infrastructure narratives against concerns over insider dumping and price volatility. While some community members are betting on a recovery supported by lock-up periods and potential institutional partnerships, others remain skeptical, framing the recent price action as a classic pump-and-dump cycle.

Alchemy Pay

Alchemy Pay is seeing heightened community discussion driven by anticipation of its upcoming L1 blockchain mainnet and ongoing regulatory expansion, with investors actively debating its long-term potential compared to similar payment-focused tokens. While some users express frustration over stagnant price action and supply unlocking, bulls are highlighting recent partnerships and broader infrastructure development as key catalysts for future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street analysts downgraded Regulus Therapeutics on Wednesday following its acquisition by Swiss drugmaker Novartis, citing limited room for upside after the deal valued Regulus at up to $1.7 billion.JonesResearch cut its rating to ‘Hold’ from ‘Buy’ and lowered its price target to $7 from $8, calling the offer “highly favorable” in light of Regulus’ upcoming Phase 3 trial financing needs, according to The Fly.Canaccord Genuity also&nbsp;reportedly downgraded the stock to ‘Hold,’ slashing its target to $11 from $28.&nbsp;Meanwhile,&nbsp;Wells Fargo reportedly cut its rating on Regulus to ‘Equal Weight’ from ‘Overweight,’ raising its target to $9 from $6 to reflect the contingent value right (CVR) component. Leerink Partners and Oppenheimer issued similar downgrades.Under the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/regulus-therapeutics-stock-rockets-on-novartis-buy-offer/chXTfRKRbiP">agreement</a>, Regulus shareholders will receive $7 per share in cash and an additional $7 via a CVR, contingent on U.S. regulatory approval of its lead candidate, farabursen.&nbsp;The upfront payment represents a 108% premium to Regulus’ April 29 closing price and a 274% premium to its 60-day volume-weighted average.&nbsp;The transaction, unanimously approved by both companies’ boards, is expected to close in the second half of 2025, pending regulatory approvals and majority shareholder tender.Shares of Regulus surged to their highest levels since 2021 following the news and are up 6.4% year-to-date, while Novartis has gained 4.8%, both outperforming broader markets.The Dow is down 4.1%, the S&amp;P 500 has lost 5.1%, and the Nasdaq is off 1.6% over the same period.On Stocktwits, 24-hour message volume for Regulus jumped by 2,863% amid “extremely bullish” sentiment.One user congratulated Regulus shareholders, particularly recent buyers, and suggested that the growing interest in rare diseases could make companies like Protalix BioTherapeutics, Zevra Therapeutics, and Esperion Therapeutics potential targets going forward.<stembedurl>https://stocktwits.com/OldManLogan/message/613115970</stembedurl>Another Stocktwits user speculated that Regulus shares could double from current levels, fueled by FDA-related optimism and the potential for a competing bid to top Novartis' offer.<stembedurl>https://stocktwits.com/ST_Tropez_Trading/message/613203730</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regulus Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead

Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a higher bid or FDA-driven gains.

Equity

Shares of biopharmaceutical company Regulus Therapeutics Inc. (RGLS) shot up 138% at the opening bell on Wednesday after Swiss drugmaker Novartis agreed to acquire the firm for up to $1.7 billion.As per the terms of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.regulusrx.com/2025-04-30-Regulus-Therapeutics-Enters-into-Agreement-to-be-Acquired-by-Novartis-AG">deal</a>, Novartis, through a subsidiary, will initiate a tender offer to acquire all of Regulus' outstanding shares for an initial price of $7.00 per share or $800 million. The initial per-share price represents a premium of 108% to Regulus' closing price on April 29.Regulus shareholders will also receive a contingent value right (CVR) of $7.00 per share if its lead product candidate, farabursen, receives regulatory approval.The total consideration, including the CVR, would be approximately $1.7 billion.Regulus’ farabursen is an investigational microRNA inhibitor designed to reduce the growth of cysts and kidney size, as well as delay progression of disease severity in a severe kidney disease called autosomal dominant polycystic kidney disease (ADPKD).Novartis President Shreeram Aradhye noted that there are limited treatment options currently available for ADPKD.“The team at Regulus has done meaningful foundational work with farabursen, and we look forward to investigating its potential further as we aim to bring a better treatment option to patients in need," he said.The transaction is expected to be completed in the second half of 2025. Until then, Regulus will continue to operate as a separate and independent company. Following the completion of the deal, Regulus will become an indirect wholly-owned subsidiary of Novartis.<a href="https://stocktwits.com/symbol/RGLS">RGLS stock</a> is up by 397% so far this year and by 237% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/humana-reports-upbeat-q1-earnings/chXT9duRbiT">Humana Reports Upbeat Q1 Earnings, Reaffirms Full-Year Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis

According to the terms of the deal, Novartis, through a subsidiary, will initiate a tender offer to acquire all of Regulus' outstanding shares for an initial price of $7.00 per share or $800 million.

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.

RGLS
Regulus Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RGLS News

RGLSRegulus Therapeutics Inc